ReviewPaediatric drugs2023
Sodium Thiosulfate: Pediatric First Approval.
Review in Paediatric drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 51 citations in OpenAlex.
- Randomized Phase Ib Clinical Trial of DB-020 Intratympanic Injections to Reduce High-Dose Cisplatin Ototoxicity.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Advances in the clinical applications of sodium thiosulphate.Annals of medicine · 2026Review
- The ubiquitin-proteasome system and proteostasis in the cochlea and sensorineural hearing disorders.Molecular biomedicine · 2026Review
- A viscosity-tunable microgel-in-sol phase for localized inner ear delivery of small hydrophilic drug.Materials today. Bio · 2026Article
- Schizantherin B alleviates cisplatin-induced ototoxicity and does not interfere cisplatin-based chemotherapy in a breast cancer model.Archives of toxicology · 2026Article
- Cancer therapy-induced ototoxicity: Current challenges and emerging management strategies.Animal models and experimental medicine · 2026Review
- Eleutheroside E alleviates cisplatin-induced ototoxicity by down-regulating MAPK/NF-κB/NLRP3 signaling pathway and inhibiting cochlear cell pyroptosis.Communications biology · 2026Article
- The inner ear immune microenvironment in sensorineural hearing loss: mechanisms and therapeutic perspectives.Frontiers in immunology · 2026Review
- Liposome-Encapsulated Rutin Attenuates Cisplatin-Induced Ototoxicity via Suppression of P53-Associated Oxidative Injury.Biomaterials research · 2026Article
- Pharmacological Inhibition of JAK/STAT-IL2 Axis Alleviated Cisplatin-Induced Ototoxicity.Molecular neurobiology · 2025Article
- Polyphenolic compounds as protective agents against cisplatin-induced ototoxicity with molecular mechanisms and clinical potential.RSC medicinal chemistry · 2025Review
- From Ototoxicity to Otoprotection: Mechanism and Protective Strategies in Cisplatin Therapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Development and Validation of a Novel Prediction Model for Hearing Loss From Cisplatin Chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Protective Effect of Selegiline (R-deprenyl) in Aminoglycoside-Induced Hearing Loss.Neurochemical research · 2025Article
- Cisplatin-Induced APE2 Overexpression Disrupts MYH9 Function and Causes Hearing Loss.Cancer research communications · 2025Article
- Approaches to Reduce Toxicity in Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2025Review
- Identification of druggable binding sites and small molecules as modulators of TMC1.Communications biology · 2025Article
- Strategies to Mitigate Cisplatin-Induced Ototoxicity: A Literature Review of Protective Agents, Mechanisms, and Clinical Gaps.Audiology research · 2025Review
- Oseltamivir (Tamiflu), a commonly prescribed antiviral drug, mitigates hearing loss in mice.Clinical and translational medicine · 2024Article
- Use of Sodium Thiosulfate as an Otoprotectant in Patients With Cancer Treated With Platinum Compounds: A Review of the Literature.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium thiosulfate (Pedmark
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.